The Study of MicroRNA Genomics of Blood Stasis Syndrome and of Coronary Heart Disease

The Analysis of Blood Stasis Syndromeand of Coronary Heart Disease Related MicroRNA Genomics and Target Gene Regulatory Networks

Status

UNKNOWN

Phases

Phase 2

Study type

Interventional

Source

ClinicalTrials.gov

Registry ID

NCT01615003

Enrollment

Registered

2012-06-08

Start date

2012-05-31

Completion date

2014-12-31

Last updated

2014-01-14

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Blood Stasis Syndrome, Coronary Heart Disease, Unstable Angina

Keywords

MicroRNA, coronary heart disease, unstable angina, blood stasis syndrome, Xuesaitong soft capsule

Brief summary

In this study, typical cases of blood stasis syndrome of coronary heart disease are selected, by using microRNA chip, cDNA microarray and other bioinformatics technologies to filter and verify related miRNA and its target gene of Coronary Heart disease. Meanwhile, intervene by Xuesaitong soft capsules to investigate related miRNA and its target gene of Coronary Heart disease.

Interventions

DRUGXuesaitong soft capsule

Xuesaitong soft capsule, soft capsule, Ingredients:PNS, Specification:0.33 per bag, once take two pills and twice a day during a month.

DRUGXuesaitong soft capsule Placebo

Xuesaitong soft capsule Placebo, soft capsule, once take two pills and twice a day during a month.

Study design

Allocation

RANDOMIZED

Intervention model

PARALLEL

Primary purpose

TREATMENT

Masking

QUADRUPLE (Subject, Caregiver, Investigator, Outcomes Assessor)

Eligibility

Sex/Gender

ALL

Age

30 Years to 75 Years

Healthy volunteers

Inclusion criteria

* Clinical diagnosis of coronary angiography unstable angina * Clinical diagnosis of unstable angina * Age of 30 to 75 years old * Not use thrombolysis, dilate coronary drugs within two weeks * Tongue dark * Sign the consent

Exclusion criteria

* Severe valvular heart disease * Insulin-dependent diabetes * mental disease * Combined with severe liver, kidney, hematopoietic system disorder * Patients with malignant tumors * Pregnancy or breast-feeding women * Recent history of trauma * Drug allergy

Design outcomes

Primary

Measure	Time frame	Description
the change of Cycle threshold of relational microRNA in coronary artery disease with unstable angina	1 month	The change of Cycle threshold of relational microRNA in coronary artery disease with unstable angina by real RT-PCR.

Countries

China

Contacts

Primary ContactFei Teng, master

echo-teng@126.com13581985462

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026